| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 347.10 | 43.4% | 43.3% |
| Total Income | 347.10 | 43.4% | 43.3% |
| Expenditure | 341.00 | 43.8% | 44.3% |
| PBT | -16.70 | 0.6% | 27.5% |
| Net Profit | -8.90 | 55.0% | 40.7% |
| OPM | 1.76% | 0.27pp | 0.68pp |
| NPM | -2.56% | 5.62pp | 3.63pp |
| EPS | -0.71 | 57.5% | 39.8% |
INNOVATE Corp.: Reports Q3 2025 Revenue Increase of $104.9M, Up 43.3%
04 May 2026 · 4 May, 7:23 am
Summary
INNOVATE Corp. reported a revenue increase of $104.9 million, or 43.3%, in Q3 2025, primarily driven by the Infrastructure segment. The adjusted EBITDA increased by $3.0 million to $19.8 million. DBM Global Inc.'s adjusted backlog increased by approximately $0.5 billion since the end of 2024, reaching $1.6 billion. MediBeacon received full regulatory approval in China for the Lumitrace® injection. R2 Technologies, Inc. experienced significant revenue growth, with year-to-date revenue increasing by approximately 65% over the same period in 2024.
Key Highlights
- 1
INNOVATE Corp.'s revenue increased by $104.9 million, or 43.3%, primarily driven by the Infrastructure segment in Q3 2025.
- 2
DBM Global Inc.'s adjusted backlog was $1.6 billion in the third quarter, an increase of approximately $0.5 billion since the end of 2024.
- 3
MediBeacon received full regulatory approval from China's National Medical Products Administration for the Lumitrace® injection.
- 4
R2 Technologies, Inc. grew revenue 3.3% to $3.1 million over the prior year period, achieving year-to-date revenue of $9.4 million, representing an approximate 65% increase over the same period in 2024.
- 5
Spectrum reported third quarter revenue of $5.6 million and Adjusted EBITDA of $1.0 million.
- 6
Year-to-date revenue reached $836.4 million for INNOVATE Corp.
- 7
Adjusted EBITDA increased by $3.0 million to $19.8 million in Q3 2025.
Informational and educational content only. Not investment advice.